ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0566

SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children

Ki Pui Lam1, Marcos H. Chinas2, Amélie M. Julé2, Maria Taylor3, Mary Beth F. Son1, Janet Chou2, Jane W. Newburger4, Adrienne G. Randolph5, Maria Gutierrez-Arcelus2 and lauren henderson1, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 3Division of Immunology, Boston Children's Hospital, Brighton, MA, 4Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 5Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: COVID-19, Inflammation, Pediatric rheumatology, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Pediatric Rheumatology – Basic Science

Session Type: Abstract Session

Session Time: 8:00AM-9:00AM

Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) develops about a month after SARS-CoV-2 infection and this delayed presentation suggests a role for the adaptive immune system. While the majority of children with MIS-C generate antibodies that neutralize SARS-CoV-2, less is known about antigen-specific T cells. We sought to characterize T cell responses in MIS-C compared to COVID-19 and pediatric hyperinflammatory syndromes.

Methods: Children with MIS-C (CDC or WHO case definitions) and COVID-19 were recruited from our center (5/2020-4/2021) and provided blood samples. Severe MIS-C was defined as ICU admission or development of coronary artery aneurysms. Children with systemic juvenile idiopathic arthritis (ILAR criteria), macrophage activation syndrome (MAS) (2016 MAS in sJIA Classification Criteria), Kawasaki disease (American Heart Association criteria), and fever unrelated to SARS-CoV-2 served as comparison subjects. To characterize the T cell repertoire, genomic DNA was used to sequence the T cell receptor (TCR) beta chain (Adaptive Biotechnologies). HLA-typing was performed by the Red Cross. The ImmuneCODE database was sourced to provide T cell repertoire data from adults with COVID-19 and TCR sequences that recognize SARS-CoV-2. Antigen specific T cells were identified by stimulating T cells with SARS-CoV-2 peptides and measuring CD40 ligand (CD40L) expression by flow cytometry.

Results: Clinical characteristics of the patients are in Table 1. TRBV11-2 gene usage was increased in MIS-C patients who tested positive for SARS-CoV-2 (MIS-Cpos, n=19) compared to all other pediatric cohorts (p< 0.0001) and adults with COVID-19 in the ImmuneCODE database (Fig1). A small number of adults (4/159) in the COVID-19 recovered group had increased Vβ11-2+ T cells. Children diagnosed with MIS-C by their providers but were negative for SARS-CoV-2 by PCR and serology (MIS-Cneg, n=5) did not display Vβ skewing. Disease severity, prior immunomodulatory treatment, age, time to sample collection, and HLA typing were not significantly associated with expansion of Vβ11-2+T cells in MIS-Cpos patients (Fig1). In T cells expressing TRBV11-2, Jβ gene pairing was polyclonal. There was a trend towards expanded SARS-CoV-2-specific TCRs in MIS-Cpos patients that was statistical significant when compared to febrile controls (p=0.03)(Fig2). TRBV11-2 gene usage was not enriched in SARS-CoV-2-specific TCRs of MIS-Cpos patients when compared to pediatric COVID-19. The viral antigens recognized by SARS-CoV-2-specific TCRs were similar in children with MIS-C and COVID-19 (Fig2). CD40L+ T cells were identified in children with MIS-Cpos after stimulation with SARS-CoV-2 peptides at frequencies comparable to children with convalescent COVID-19 (Fig 2). There was no difference in the frequency of CD40L+ T cells in MIS-Cpos patients based on disease severity.

Conclusion: Expansion of Vβ11-2+ T cells was a specific biomarker of MIS-C patients with laboratory confirmed SARS-CoV-2 infections and was not found in COVID-19 or pediatric hyperinflammatory syndromes. Children with MIS-C had robust antigen-specific T cell responses to SARS-CoV-2 that were comparable to pediatric patients with COVID-19.

Supporting image 1

Supporting image 2

Figure 1. Increased Usage of TRBV11_2 in T cells from patients with MIS-C. A) The frequency of T cell clonotypes expressing TRBV11_2 in each study group. Statistical analysis: two-way ANOVA comparing study group and Vβ gene with the Dunnett’s multiple comparisons test. The frequency of T cell clonotypes expressing TRBV11_2 in patients with B) moderate vs. severeª MIS-C SARSCoV2pos and C) patients with MIS-C SARSCoV2pos who received prior immunomodulatory treatment vs. those who were treatment naïve. The relationship between the frequency of T cell clonotypes expressing TRBV11_2 and D) the age and E) time from hospital admission to biosample collection in patients with MIS-C SARSCoV2pos. Statistical analysis: Spearman’s non-parametric rank correlation. F) The frequency of T cell clonotypes expressing TRBV11_2 in MIS-C SARSCoV2pos and adults in the ImmuneCODE database. Statistical analysis: Wilcoxon test. Summary data on bar graphs is mean ± standard error in A-E and median with IQR in F. P value, **** ≤ 0.0001, ***=0.001, **=0.01, *=0.05.

SARS-CoV_2, severe acute respiratory syndrome coronavirus 2; MIS-C, multisystem inflammatory syndrome in children; peds, pediatric; ctrl, control; KD, Kawasaki disease; sJIA, systemic juvenile idiopathic arthritis; MAS, macrophage activation syndrome; Tx, treatment.

ª Severe MIS-C was defined by admission to the intensive care unit or development of coronary artery aneurysms (CAAs) (z-score ≥ 2.5).

Supporting image 3

Figure 2. SARS-CoV_2 Specific T Cell Responses in MIS-C. SARS-CoV_2 specific TCR sequences were obtained from the ImmuneCODE database. Antigen-specific T cells were identified by the expression of activation markers following exposure to SARS-CoV_2 peptides. These T cells were then isolated for TCR sequencing. A) The median frequency with IQR of the top 10 most abundant SARS-CoV_2-specific TCRs. B-C) Viral antigens recognized by SARS-CoV_2-specific TCRs in B) MIS-C SARSCOV2pos and C) pediatric COVID_19. D-E) Peripheral blood mononuclear cells were incubated with either water (negative control) or peptide pools covering the S1, N, and M viral proteins. SARS-CoV_2 -specific T cells were identified by their expression of CD154 (CD40 ligand). D) Flow cytometry dot plots depicting CD40L expression on T cells from a healthy control, child with convalescent COVID_19ª, and child with MIS-C SARSCOV2pos. E) Frequency of CD4+CD40L+ or CD8+CD40L+ T cells in the given study group. Summary data on bar graphs is mean ± standard error. P value * ≤ 0.05, ** ≤ 0.01.

SARS-CoV_2, severe acute respiratory syndrome coronavirus 2; MIS-C, multisystem inflammatory syndrome in children; peds, pediatric; ctrl, control; TCR, T cell receptor.

ª Blood samples obtained greater than 2 weeks after a positive PCR for SARS-CoV_2 were classified as convalescent COVID_19.


Disclosures: K. Lam, None; M. Chinas, None; A. Julé, None; M. Taylor, None; M. Son, None; J. Chou, None; J. Newburger, None; A. Randolph, None; M. Gutierrez-Arcelus, None; l. henderson, Sobi, Pfizer, Adaptive Biotechnologies, BMS.

To cite this abstract in AMA style:

Lam K, Chinas M, Julé A, Taylor M, Son M, Chou J, Newburger J, Randolph A, Gutierrez-Arcelus M, henderson l. SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/sars-cov-2-specific-t-cell-responses-in-multisystem-inflammatory-syndrome-in-children/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sars-cov-2-specific-t-cell-responses-in-multisystem-inflammatory-syndrome-in-children/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology